Hu Xiao-Nan, Li Chun-Feng, Huang Si-Meng, Nie Chun-Lei, Pang Rui
Department of Head and Neck Radiotherapy Ward, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China.
Department of Gastrointestinal Surgical Ward, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China.
World J Gastroenterol. 2025 May 21;31(19):106644. doi: 10.3748/wjg.v31.i19.106644.
Gastric cancer (GC) and head and neck squamous cell carcinoma (HNSCC) are common malignancies with high morbidity and mortality rates. Traditional treatments often yield limited efficacy, especially in advanced cases. Recent advancements in immunotherapy, particularly immune checkpoint inhibitors targeting programmed death-ligand 1 (PD-L1), have shown promise. However, the expression and interaction of pescadillo ribosomal biogenesis factor 1 (PES1) and PD-L1 in these cancers remain unclear. Understanding their roles could provide new insights into tumor biology and improve therapeutic strategies.
To investigate the expression levels of PES1 and PD-L1 in tumor tissues of patients with GC and HNSCC.
A total of 58 cases of GC and HNSCC undergoing surgical resection were selected from January 2022 to January 2024. Paraffin specimens of GC and HNSCC tissues were taken from the patients, and the sections were subjected to staining with immunohistochemistry and hematoxylin-eosin staining, and the protein expression of PES1 and PD-L1 was observed microscopically.
Among 58 GC and HNSCC tissues, 30 cases were positive and 28 cases were negative for PES1 expression, and 34 cases were positive and 24 cases were negative for PD-L1 expression. The positive expression rates of PES1 and PD-L1 were 51.72% and 58.62%, respectively. PES1 expression was correlated with the TNM stage, lymph node metastasis, and the depth of infiltration ( < 0.05), and PD-L1 expression was correlated with the differentiation degree, lymph node metastasis, and infiltration depth ( < 0.05).
PES1 and PD-L1 were positively expressed in GC and HNSCC tissues and correlated with clinical features. They may serve as potential biomarkers for immune-targeted therapies.
胃癌（GC）和头颈部鳞状细胞癌（HNSCC）是发病率和死亡率较高的常见恶性肿瘤。传统治疗方法往往疗效有限，尤其是在晚期病例中。免疫疗法的最新进展，特别是针对程序性死亡配体1（PD-L1）的免疫检查点抑制剂，已显示出前景。然而，在这些癌症中，pescadillo核糖体生物发生因子1（PES1）和PD-L1的表达及相互作用仍不清楚。了解它们的作用可为肿瘤生物学提供新见解并改善治疗策略。
研究GC和HNSCC患者肿瘤组织中PES1和PD-L1的表达水平。
选取2022年1月至2024年1月期间接受手术切除的58例GC和HNSCC患者。采集患者的GC和HNSCC组织石蜡标本，切片进行免疫组织化学和苏木精-伊红染色，显微镜下观察PES1和PD-L1的蛋白表达。
在58例GC和HNSCC组织中，PES1表达阳性30例，阴性28例；PD-L1表达阳性34例，阴性24例。PES1和PD-L1的阳性表达率分别为51.72%和58.62%。PES1表达与TNM分期、淋巴结转移及浸润深度相关（<0.05），PD-L1表达与分化程度、淋巴结转移及浸润深度相关（<0.05）。
PES1和PD-L1在GC和HNSCC组织中呈阳性表达且与临床特征相关。它们可能作为免疫靶向治疗的潜在生物标志物。
